Tongmai Yangxin Pill combined with metoprolol or metoprolol alone for the treatment of symptomatic premature ventricular complex: a multicenter, randomized, parallel-controlled clinical study

Li-Jun Liu, Guohua Zhu, Hong Luo, Xi-peng Sun, Jing Li, Qifeng Hua
{"title":"Tongmai Yangxin Pill combined with metoprolol or metoprolol alone for the treatment of symptomatic premature ventricular complex: a multicenter, randomized, parallel-controlled clinical study","authors":"Li-Jun Liu, Guohua Zhu, Hong Luo, Xi-peng Sun, Jing Li, Qifeng Hua","doi":"10.11909/j.issn.1671-5411.2022.04.008","DOIUrl":null,"url":null,"abstract":"OBJECTIVE To investigate the effects of Tongmai Yangxin Pill (TMYXP) combined with metoprolol tartrate or metoprolol alone for the treatment of premature ventricular complex (PVC) in patients with symptomatic frequent PVC. METHODS A total of 584 patients with symptomatic frequent PVC were randomly assigned (in a 1:1 ratio) into two groups: study group [n = 292, TMYXP (40 pills twice/day, orally) combined with metoprolol tartrate (25 mg twice/day, orally)] and control group [n = 292, metoprolol tartrate (25 mg twice/day, orally) plus placebo pill (40 pills twice/day, orally)]. The total treatment period was eight weeks. RESULTS After eight weeks of treatment, the total effective rate of reduction of PVC in the study group and the control group were 76.4% and 51.4%, respectively (P < 0.001). TMYXP combined with metoprolol tartrate demonstrated a significantly greater reduction of the frequency of PVCs compared with the metoprolol tartrate alone (−4537 times/24 h vs. −3013 times/24 h, P < 0.001). The study group also showed a better result compared with the control group with respect to PVC related symptoms. In terms of New York Heart Association classification improvement, the total effective rates were 21.9% in the study group and 12.4% in the control group ( P < 0.05). Both the study group and the control group exhibited improvements in echocardiographic indexes. Left ventricular ejection fraction was significantly improved in the study group compared with the control group ( P < 0.05). There was no significant difference in the incidence of adverse events between the two groups. CONCLUSIONS Compared with metoprolol tartrate alone, TMYXP combined with metoprolol tartrate could more effectively reduce the frequency of PVC and alleviated PVC related symptoms, and improve cardiac function in patients with symptomatic PVC.","PeriodicalId":285674,"journal":{"name":"Journal of geriatric cardiology : JGC","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of geriatric cardiology : JGC","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11909/j.issn.1671-5411.2022.04.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVE To investigate the effects of Tongmai Yangxin Pill (TMYXP) combined with metoprolol tartrate or metoprolol alone for the treatment of premature ventricular complex (PVC) in patients with symptomatic frequent PVC. METHODS A total of 584 patients with symptomatic frequent PVC were randomly assigned (in a 1:1 ratio) into two groups: study group [n = 292, TMYXP (40 pills twice/day, orally) combined with metoprolol tartrate (25 mg twice/day, orally)] and control group [n = 292, metoprolol tartrate (25 mg twice/day, orally) plus placebo pill (40 pills twice/day, orally)]. The total treatment period was eight weeks. RESULTS After eight weeks of treatment, the total effective rate of reduction of PVC in the study group and the control group were 76.4% and 51.4%, respectively (P < 0.001). TMYXP combined with metoprolol tartrate demonstrated a significantly greater reduction of the frequency of PVCs compared with the metoprolol tartrate alone (−4537 times/24 h vs. −3013 times/24 h, P < 0.001). The study group also showed a better result compared with the control group with respect to PVC related symptoms. In terms of New York Heart Association classification improvement, the total effective rates were 21.9% in the study group and 12.4% in the control group ( P < 0.05). Both the study group and the control group exhibited improvements in echocardiographic indexes. Left ventricular ejection fraction was significantly improved in the study group compared with the control group ( P < 0.05). There was no significant difference in the incidence of adverse events between the two groups. CONCLUSIONS Compared with metoprolol tartrate alone, TMYXP combined with metoprolol tartrate could more effectively reduce the frequency of PVC and alleviated PVC related symptoms, and improve cardiac function in patients with symptomatic PVC.
通脉养心丸联合美托洛尔或单用美托洛尔治疗症状性室性早泄的多中心、随机、平行对照临床研究
目的探讨通脉养心丸(TMYXP)联合酒石酸美托洛尔或单独美托洛尔治疗有症状的频繁室性早搏(PVC)的疗效。方法将584例有症状的频繁PVC患者随机分为两组(按1:1比例):研究组[n = 292, TMYXP(40粒,2次/天,口服)联合酒石酸美托洛尔(25 mg, 2次/天,口服)]和对照组[n = 292,酒石酸美托洛尔(25 mg, 2次/天,口服)+安慰剂丸(40粒,2次/天,口服)]。总治疗期为8周。结果治疗8周后,研究组和对照组的总有效率分别为76.4%和51.4% (P < 0.001)。与单独使用酒石酸美托洛尔相比,TMYXP联合使用酒石酸美托洛尔可显著降低室性早搏频率(- 4537次/24 h vs - 3013次/24 h, P < 0.001)。与对照组相比,研究组在与PVC相关的症状方面也显示出更好的结果。在纽约心脏协会分级改善方面,研究组总有效率为21.9%,对照组总有效率为12.4% (P < 0.05)。研究组和对照组超声心动图指标均有改善。研究组左室射血分数明显高于对照组(P < 0.05)。两组患者不良事件发生率无显著差异。结论与单用酒石酸美托洛尔相比,TMYXP联合酒石酸美托洛尔能更有效地降低PVC发生频率,缓解PVC相关症状,改善症状性PVC患者心功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信